Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- Available Integrase Inhibitors
- 4 INSTIs have been approved for use in first-line therapy regimens: raltegravir, elvitegravir, dolutegravir, and bictegravir
- 3 INSTIs are recommended as part of first-line options in EACS guidelines: raltegravir, dolutegravir, and bictegravir
- Elvitegravir is an alternative regimen option in both guidelines
- 3 INSTIs are recommended as part of first-line options in EACS guidelines: raltegravir, dolutegravir, and bictegravir
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Initial Antiretroviral Therapy